186 related articles for article (PubMed ID: 22566197)
1. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
[TBL] [Abstract][Full Text] [Related]
2. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
3.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
4. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma.
Roll W; Müther M; Sporns PB; Zinnhardt B; Suero Molina E; Seifert R; Schäfers M; Weckesser M; Stegger L; Beule AG; Stummer W; Rahbar K
World Neurosurg; 2020 Nov; 143():e391-e399. PubMed ID: 32745642
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
Puranik AD; Kulkarni HR; Singh A; Baum RP
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1223-30. PubMed ID: 25822655
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
10. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
11. Imaging-Guided Use of Combined
Ashwathanarayana AG; Biswal CK; Sood A; Parihar AS; Kapoor R; Mittal BR
J Nucl Med Technol; 2017 Dec; 45(4):314-316. PubMed ID: 28798226
[TBL] [Abstract][Full Text] [Related]
12. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
[TBL] [Abstract][Full Text] [Related]
13. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Mar; 40(3):237-40. PubMed ID: 25608146
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy for metastatic paragangliomas.
Pinato DJ; Black JR; Ramaswami R; Tan TM; Adjogatse D; Sharma R
Med Oncol; 2016 May; 33(5):47. PubMed ID: 27059363
[TBL] [Abstract][Full Text] [Related]
16. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
Basu S; Ranade R
J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; de Herder WW; Feelders RA; Krenning EP; Kwekkeboom DJ
Endocr Relat Cancer; 2017 May; 24(5):243-251. PubMed ID: 28320783
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
[TBL] [Abstract][Full Text] [Related]
19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
20. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors.
Adnan A; Kudachi S; Ramesh S; Prabhash K; Basu S
Nucl Med Commun; 2019 Sep; 40(9):947-957. PubMed ID: 31343606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
